BRPI0815681A2 - Uso de um inibidor de mieloperoxidase, métodos para o tratamento de atrofia sistema múltipla, e da doença de huntington, e, método para neuroproteção. - Google Patents

Uso de um inibidor de mieloperoxidase, métodos para o tratamento de atrofia sistema múltipla, e da doença de huntington, e, método para neuroproteção.

Info

Publication number
BRPI0815681A2
BRPI0815681A2 BRPI0815681-6A2A BRPI0815681A BRPI0815681A2 BR PI0815681 A2 BRPI0815681 A2 BR PI0815681A2 BR PI0815681 A BRPI0815681 A BR PI0815681A BR PI0815681 A2 BRPI0815681 A2 BR PI0815681A2
Authority
BR
Brazil
Prior art keywords
neuroprotection
treatment
methods
multiple system
system atrophy
Prior art date
Application number
BRPI0815681-6A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Hakan Eriksson
Werner Poewe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0815681A2 publication Critical patent/BRPI0815681A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0815681-6A2A 2007-08-23 2008-08-22 Uso de um inibidor de mieloperoxidase, métodos para o tratamento de atrofia sistema múltipla, e da doença de huntington, e, método para neuroproteção. BRPI0815681A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95752507P 2007-08-23 2007-08-23
US95752307P 2007-08-23 2007-08-23
PCT/SE2008/050950 WO2009025618A1 (en) 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Publications (1)

Publication Number Publication Date
BRPI0815681A2 true BRPI0815681A2 (pt) 2015-02-18

Family

ID=40378392

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815681-6A2A BRPI0815681A2 (pt) 2007-08-23 2008-08-22 Uso de um inibidor de mieloperoxidase, métodos para o tratamento de atrofia sistema múltipla, e da doença de huntington, e, método para neuroproteção.

Country Status (25)

Country Link
US (6) US20090054468A1 (https=)
EP (1) EP2200616B1 (https=)
JP (2) JP5247804B2 (https=)
KR (1) KR101588464B1 (https=)
CN (4) CN103638029A (https=)
AU (1) AU2008289653B2 (https=)
BR (1) BRPI0815681A2 (https=)
CA (1) CA2698205C (https=)
CY (1) CY1113714T1 (https=)
DK (1) DK2200616T3 (https=)
EA (1) EA017510B1 (https=)
ES (1) ES2399846T3 (https=)
HR (1) HRP20130139T1 (https=)
IL (2) IL203738A (https=)
ME (1) ME01510B (https=)
MX (1) MX2010001983A (https=)
MY (1) MY155633A (https=)
NZ (1) NZ584135A (https=)
PH (1) PH12014501180A1 (https=)
PL (1) PL2200616T3 (https=)
PT (1) PT2200616E (https=)
RS (1) RS52665B (https=)
SI (1) SI2200616T1 (https=)
WO (1) WO2009025618A1 (https=)
ZA (1) ZA201000848B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
CN103917529B (zh) 2011-11-11 2016-08-17 辉瑞大药厂 2-硫代嘧啶酮类
JP2015512905A (ja) * 2012-03-29 2015-04-30 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 有害動物を駆除するためのｎ−置換複素二環式化合物および誘導体ｉｉ
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
AU2016257179A1 (en) 2015-05-05 2017-11-02 Pfizer Inc. 2-thiopyrimidinones
US11382918B2 (en) * 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
AU2018304508B2 (en) * 2017-07-17 2021-06-10 Astrazeneca Ab MPO inhibitors for use in medicine
CA3157260A1 (en) * 2019-10-10 2021-04-15 Biohaven Therapeutics Ltd. Prodrugs of myeloperoxidase inhibitors
WO2021178734A1 (en) * 2020-03-05 2021-09-10 Biohaven Therapeutics Ltd. Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor
CA3181917A1 (en) * 2020-05-06 2021-11-11 Biohaven Therapeutics Ltd. Process for the preparation of verdiperstat
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
CN119894896A (zh) 2022-08-18 2025-04-25 阿斯利康(瑞典)有限公司 绿过氧化物酶的抑制剂
EP4580606A1 (en) * 2022-08-31 2025-07-09 Astrazeneca AB Pharmaceutical formulation
CN120265633A (zh) * 2022-12-09 2025-07-04 深圳信立泰药业股份有限公司 一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途
WO2024163892A1 (en) * 2023-02-02 2024-08-08 University Of Virginia Patent Foundation Myeloperoxidase (mpo) inhibition as a treatment target for delayed cerebral injury (dci) in aneurysmal subarachnoid hemorrhage (sah)
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2025190901A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses
CN121378265A (zh) * 2025-10-30 2026-01-23 乐平市康鑫医药化工有限公司 一种吡唑类化合物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834500T2 (de) * 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
KR101098209B1 (ko) * 2002-01-28 2011-12-23 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료 방법
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
CN101460501A (zh) * 2006-06-05 2009-06-17 阿斯利康(瑞典)有限公司 作为髓过氧化物酶抑制剂的吡咯并[3，2-d]嘧啶-4-酮衍生物
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Also Published As

Publication number Publication date
PL2200616T3 (pl) 2013-04-30
SI2200616T1 (sl) 2013-03-29
EP2200616A4 (en) 2010-08-25
US20110207755A1 (en) 2011-08-25
US10772890B2 (en) 2020-09-15
PH12014501180A1 (en) 2015-08-24
JP5247804B2 (ja) 2013-07-24
ZA201000848B (en) 2012-07-25
PT2200616E (pt) 2013-02-27
MY155633A (en) 2015-11-13
KR20100055434A (ko) 2010-05-26
AU2008289653B2 (en) 2012-06-28
IL240130A0 (en) 2015-09-24
MX2010001983A (es) 2010-03-10
US20090054468A1 (en) 2009-02-26
CN105687199A (zh) 2016-06-22
CN103638029A (zh) 2014-03-19
IL203738A (en) 2015-08-31
JP2010536849A (ja) 2010-12-02
CA2698205C (en) 2016-06-21
CN101873857A (zh) 2010-10-27
US20130059870A1 (en) 2013-03-07
RS52665B (sr) 2013-06-28
WO2009025618A1 (en) 2009-02-26
HK1145141A1 (en) 2011-04-08
ES2399846T3 (es) 2013-04-03
NZ584135A (en) 2012-04-27
DK2200616T3 (da) 2013-03-04
KR101588464B1 (ko) 2016-01-25
HRP20130139T1 (hr) 2013-03-31
JP2013151547A (ja) 2013-08-08
EA017510B1 (ru) 2013-01-30
EP2200616A1 (en) 2010-06-30
CN113633641A (zh) 2021-11-12
US20190099423A1 (en) 2019-04-04
CY1113714T1 (el) 2016-06-22
AU2008289653A1 (en) 2009-02-26
US20200405724A1 (en) 2020-12-31
EP2200616B1 (en) 2012-12-26
EA201000202A1 (ru) 2010-10-29
ME01510B (me) 2014-04-20
CA2698205A1 (en) 2009-02-26
US20140221400A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
BRPI0815681A2 (pt) Uso de um inibidor de mieloperoxidase, métodos para o tratamento de atrofia sistema múltipla, e da doença de huntington, e, método para neuroproteção.
BRPI0717480A2 (pt) Método e sistema para tratamento de um alimentação de hidrocarboneto, e, composição de hidrocarboneto.
BRPI0720349A2 (pt) Método para operar um instrumento acoplado com um sistema microcirúrgico.
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
NL2003118A1 (nl) Alignment system, lithographic system and method.
BRPI0819127A2 (pt) Método para cimentar.
BRPI0811883A2 (pt) Método e sistema para planejamento dentário.
BRPI0716172A2 (pt) instalaÇço de remoÇço de revestimento e mÉtodo para operaÇço da mesma.
BRPI0817872A2 (pt) sistema para tratamento de um paciente que apresenta um distúrbio intestinal.
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0810356A2 (pt) Sistema de aquecimento para uma formação de subsuperfície, e, método para aquecer uma formação de subsuperfície.
BRPI0716696A2 (pt) Sistema de aplicação para tratamento remoto de um animal
BRPI0813146A2 (pt) Método para operar uma instalação de gado, método para controlar gado, e, sistema de processamento de gado
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
BRPI0811048A2 (pt) Sistema e método para criar uma lista de informações compartilhadas em uma rede não-herárquica.
BRPI0819842A2 (pt) Sistema de carga e método para operar o mesmo.
BRPI0815707A2 (pt) Processo para a liquefação de uma corrente gasosa, e, sistema para o tratamento de uma corrente de alimentação gasosa.
BRPI0818426A2 (pt) produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI0812508A2 (pt) Dispositivo e processo para controlar um dispositivo de freio.
BRPI0907054A2 (pt) sistema de aeronave, e, método para operar um sistema de aeronave
BRPI0823030A2 (pt) Sistema de elevador, e, método para fazer um sistema de elevador.
BRPI0811113A2 (pt) Processo, aparelho e sistema para estabelecer conexão.
BRPI0808030A2 (pt) Método para desobstruir um tubo de conteúdos com um sistema pneumático, e, sistema de desobstrução para um tubo.
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]